Sugi Predict

Sugi Predict / Targets / ZRANB2

ZRANB2

Zinc finger Ran-binding domain-containing protein 2 · O95218 · ZRANB2 on Sugi Atlas →

1,829 patent compounds predicted against ZRANB2, 1,616 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
Molibresib Molibresib (SCHEMBL1872390) 1.00 1/20
Molibresib Molibresib (SCHEMBL12671490) 1.00 1/20
Molibresib Molibresib (SCHEMBL12966358) 1.00 1/20
SCHEMBL9998851 SCHEMBL9998851 0.91 1/20
SCHEMBL14756282 SCHEMBL14756282 0.88 1/20
SCHEMBL15980874 SCHEMBL15980874 0.88 1/20
SCHEMBL12966165 SCHEMBL12966165 0.87 1/20
SCHEMBL14756215 SCHEMBL14756215 0.87 1/20
SCHEMBL14756339 SCHEMBL14756339 0.87 1/20
SCHEMBL15980861 SCHEMBL15980861 0.87 1/20
SCHEMBL9998825 SCHEMBL9998825 0.86 1/20
SCHEMBL15980893 SCHEMBL15980893 0.86 1/20
SCHEMBL15980803 SCHEMBL15980803 0.86 1/20
SCHEMBL1874116 SCHEMBL1874116 0.85 1/20
SCHEMBL12671221 SCHEMBL12671221 0.85 1/20
SCHEMBL14756021 SCHEMBL14756021 0.85 1/20
SCHEMBL14756240 SCHEMBL14756240 0.85 1/20
SCHEMBL14756287 SCHEMBL14756287 0.85 1/20
SCHEMBL14756335 SCHEMBL14756335 0.85 1/20
SCHEMBL14756409 SCHEMBL14756409 0.85 1/20

Clinical trials — most relevant to ZRANB2 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Efficacy and Safety Assessment of Oral LBH589 in Adult Patients With Advanced Soft TIssue Sarcoma After Pre-treatment Failure PHASE2COMPLETED
Safety and Dose Escalation Study of Zinc Supplementation in Critically Ill Children PHASE1/PHASE2COMPLETED
Clinical Study of EBV-LMP1 Targeted DNAzyme to Treat Nasopharyngeal Carcinoma PHASE1/PHASE2COMPLETED
Zinc Sulphate in Treatment Fibrosis in HBV Patient Receiving Antiviral Therapy PHASE2NOT_YET_RECRUITING
Study of the Beach Regimen on Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) PHASE2ACTIVE_NOT_RECRUITING
Treatment With Azacitidine of Recurrent Gliomas With IDH1/2 Mutation PHASE2UNKNOWN
A Phase I Study of 5-Azacytidine in Combination With Chemotherapy for Children With Relapsed or Refractory ALL or AML PHASE1COMPLETED
Evaluation of the Safety and the Tolerability of a Combination of Two HIV Inducers in Patients With Undetectable Viral Load PHASE1COMPLETED
Amplification of Zinc Finger Protein 217 Gene in Multiple Myeloma nanUNKNOWN
Zinc and the Synthesis of Zinc Binding Proteins (Protocol B) nanCOMPLETED
Study of Proteins in Head and Neck Cancer Cells nanCOMPLETED
PHF19 Gene Expression and EZH2 Gene Deletion in Acute Myeloid Leukemia nanUNKNOWN
Characterization of Microbiological and Genetic Features in Prostate Cancer and Their Association with Disease Stage nanENROLLING_BY_INVITATION
A Prospective Study of Molecular Detection of Salvageable Early Recurrent Nasopharyngeal Carcinoma After Radiotherapy nanCOMPLETED
Gene Expression Variation and Implant Wound Healing Among Smokers and Diabetics nanCOMPLETED
Novel Biomarkers in the Neoplastic Progression of Barrett's Esophagus nanACTIVE_NOT_RECRUITING
Prevalence of a Non-Expressing 11B Mutation in Aka Peoples of the Central African Republic nanCOMPLETED
Detection of IKZF1 Deletion Mutation in Patients With Acute Lymphoblastic Leukemia and Its Impact in Therapy nanUNKNOWN
Association of SNPs in Long Intergenic Noncoding RNA 00511 (LINC00511) With Breast Cancer Among the Egyptian Population nanCOMPLETED
Immunophenotyping and Xist Gene in AML nanUNKNOWN
EKLF Gene Expression in β-thalassemia nanNOT_YET_RECRUITING
Genetic Analysis of Heart Channelopathies in Brazilian Patients and Their Relatives nanUNKNOWN
Study of Tazemetostat in Adults With Follicular Lymphoma Previously Treated With at Least Two Therapies nanWITHDRAWN
DNA Methylation and Autoimmune Thyroid Diseases nanCOMPLETED
A Cohort Study on Screening and Follow-up of High-risk Population of PDAC Based on EUS nanNOT_YET_RECRUITING
Biocollection in MyeloDysplastic Syndrome (P-MDS) nanRECRUITING
MiRNA223 and HMGB1 as Apredictos for Drug Resistant Epilepsy nanUNKNOWN
Longitudinal Studies of Patient With FPDMM nanRECRUITING
Genetic Susceptibility in MAlignant Pleural Mesothelioma: Clinical Implication of GermliNE variaTionS nanRECRUITING
Value of MicroRNA30a in Philadelphia Positive Leukemic Patients nanUNKNOWN

Related proteins — ESM-2 sequence neighbours (a ZRANB2 binder may also engage these)

ProteinNameSimilarity
Q5ZLX5 — 1.000 Q5ZLX5 →
Q5R580 — 1.000 Q5R580 →
Q9R020 — 1.000 Q9R020 →
O35986 — 1.000 O35986 →
Q19QU3 — 0.998 Q19QU3 →
P30415 — 0.986 P30415 →
Q9LY75 — 0.985 Q9LY75 →
Q5VTL8 — 0.984 Q5VTL8 →
Q9VB74 — 0.984 Q9VB74 →
Q3KPW4 — 0.984 Q3KPW4 →
Q5XHJ5 — 0.983 Q5XHJ5 →
Q3UC65 — 0.983 Q3UC65 →
Q6C1V6 — 0.982 Q6C1V6 →
P30414 — 0.982 P30414 →
Q5R8J6 — 0.981 Q5R8J6 →
Q1ECZ9 — 0.981 Q1ECZ9 →
Q66PJ3 — 0.981 Q66PJ3 →
Q94546 — 0.981 Q94546 →
Q5ZMJ9 — 0.980 Q5ZMJ9 →
Q9CVI2 — 0.980 Q9CVI2 →
Q4R626 — 0.980 Q4R626 →
Q4V8I5 — 0.980 Q4V8I5 →
Q52KI8 — 0.980 Q52KI8 →
O55035 — 0.979 O55035 →
Q55ED4 — 0.979 Q55ED4 →
Q7L4I2 — 0.979 Q7L4I2 →
A2AR02 — 0.979 A2AR02 →
YTHDC1 YTH domain-containing protein 1 0.979 landscape →
Q8IYB3 — 0.979 Q8IYB3 →
Q14AX6 — 0.978 Q14AX6 →